Australian (ASX) Stock Market Forum

PER - Percheron Therapeutics

Jump to new
ANP is my pick for the November tipping comp.
They possibly have the most promising treatment for Duchennes Muscular Dystrophy, a truly horrific disease for which there is currently no effective therapy. ANP has conducted a successful Phase 2 trial.
In the pipeline ANP has other products to tackle MS, Acromegaly and cancer.
A cap raise has stalled the rise that positive news for Europe was about to bring.
 
ANP is one of my picks in the 2022 tipping comp. Exciting new(ish) technology that provides hope for a wide range of diseases using genetic manipulation. Many of the diseases they are working on currently have little or no effective treatments. If they succeed in just one their MC will be many multiples of where it is now.
 
This could go in the potential breakout thread, or here.

Screenshot_20220901-154427.png
 
On January 4th, 2024, Antisense Therapeutics Limited (ANP) changed its name and ASX code to Percheron Therapeutics Limited (PER).
 
Percheron is my March Competition selection, this company is fully funded through to various end stage trials due in the second half of 2024. It is important to note their board is packed with experienced members able to steer the good work of researchers in this worthwhile cause with the hope will help trial participants and ultimately shareholders.
 
PER is my wildest guess entry for Jan 25 tipping.
After spending a few minutes reading the stock announcement, it was a blindfolded guess entry.
Directors spent their own money even after a failed study - why ?

Too optimistic, or is the inferred impact too little to overshadow the big picture?

1735743813959.png
1735743853248.png

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899707-3A659122 - A director bought 1.67 million SHARES
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899032-3A658994 - another director bought 1.5 m shares
Trading Halt https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02894972-3A658223'
This is the announcement on 18 Dec 24, when the CEO was disappointed with the test result but put his trust in reinvesting however

Loading...

cdn-api.markitdigital.com

1735744122693.png
 
Miner said:
PER is my wildest guess entry for Jan 25 tipping.
After spending a few minutes reading the stock announcement, it was a blindfolded guess entry.
Directors spent their own money even after a failed study - why ?

Too optimistic, or is the inferred impact too little to overshadow the big picture?

View attachment 190342View attachment 190343
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899707-3A659122 - A director bought 1.67 million SHARES
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899032-3A658994 - another director bought 1.5 m shares
Trading Halt https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02894972-3A658223'
This is the announcement on 18 Dec 24, when the CEO was disappointed with the test result but put his trust in reinvesting however

Loading...

cdn-api.markitdigital.com

View attachment 190344
Click to expand...
Another purchase by a director on 31 Dec. interesting if they are supporting my tip for Jan :) :)
 
Top